A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

NCT04041050 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloproliferative Neoplasm

Interventions

DRUG: Navitoclax
DRUG: Ruxolitinib
DRUG: Celecoxib

Sponsor

AbbVie